Skip Nav Destination
Issues
1 April 2009
-
Cover Image
Cover Image
A, T47D cells depleted of HDAC2, but not of HDAC1, showed increased DNA sensitivity to nuclease digestion by the ISNT DNA hypersensitivity assay. Cells transfected with nonsilencing siRNA followed by incubation with 2 mmol/L VPAfor 48 h served as a positive control. B, electron micrographs of cells transfected with nonsilencing siRNA or depleted of HDAC1 or HDAC2. Arrows, dense areas of heterochromatin clusters. C, stacked bar graph depicting the mean heterochromatin content (shaded) per cell per transfection condition. Heterochromatin content was determined by point-count intercept morphometry analysis of the electron micrographs for 50 cells per transfection condition. Statistical analysis by Student’s t test indicated a significant (P < 0.0001) reduction in the heterochromatin content in cells depleted of HDAC2 but not of HDAC1 compared with cells transfected with nonsilencing siRNA. For details, see Marchion et al., in this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Spotlight on Molecular Profiling
Minireview
Research Articles
AMP-activated protein kinase promotes human prostate cancer cell growth and survival
Hyeon Ung Park; Simeng Suy; Malika Danner; Vernon Dailey; Ying Zhang; Henghong Li; Daniel R. Hyduke; Brian T. Collins; Gregory Gagnon; Bhaskar Kallakury; Deepak Kumar; Milton L. Brown; Albert Fornace; Anatoly Dritschilo; Sean P. Collins
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4
Patrizia Nanni; Giordano Nicoletti; Arianna Palladini; Annalisa Astolfi; Paola Rinella; Stefania Croci; Lorena Landuzzi; Giada Monduzzi; Valeria Stivani; Agnese Antognoli; Annalisa Murgo; Marianna Ianzano; Carla De Giovanni; Pier-Luigi Lollini
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines
Eva Martinez-Balibrea; Carmen Plasencia; Alba Ginés; Anna Martinez-Cardús; Eva Musulén; Rodrigo Aguilera; José Luis Manzano; Nouri Neamati; Albert Abad
Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug
Julie Guillermet-Guibert; Lise Davenne; Dimitri Pchejetski; Nathalie Saint-Laurent; Leyre Brizuela; Céline Guilbeau-Frugier; Marie-Bernadette Delisle; Olivier Cuvillier; Christiane Susini; Corinne Bousquet
ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway
Rong Deng; Jun Tang; Liang-Ping Xia; Dan-Dan Li; Wen-Jun Zhou; Lin-Lin Wang; Gong-Kan Feng; Yi-Xin Zeng; You-Heng Gao; Xiao-Feng Zhu
Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins
Jun Wei; Shinichi Kitada; Michele F. Rega; Aras Emdadi; Hongbin Yuan; Jason Cellitti; John L. Stebbins; Dayong Zhai; Jiazhi Sun; Li Yang; Russell Dahl; Ziming Zhang; Bainan Wu; Si Wang; Tyler A. Reed; Nicholas Lawrence; Said Sebti; John C. Reed; Maurizio Pellecchia
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
Karen Lundgren; Hong Zhang; John Brekken; Nanni Huser; Rachel E. Powell; Noel Timple; David J. Busch; Laura Neely; John L. Sensintaffar; Yong-ching Yang; Andres McKenzie; Jessica Friedman; Robert Scannevin; Adeela Kamal; Kevin Hong; Srinivas R. Kasibhatla; Marcus F. Boehm; Francis J. Burrows
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects
David L. Schwartz; Garth Powis; Arun Thitai-Kumar; Yi He; James Bankson; Ryan Williams; Robert Lemos; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Ryuichi Nishii; Mian Alauddin; Uday Mukhopadhay; Zhenghong Peng; William Bornmann; Juri Gelovani
Advertisement